 |
 |
 |
|
Kaprex provides a safer option for effective joint relief. This proprietary combination of selected plant components influences kinase signaling and the formation of certain substances that are associated with minor pain. Clinical testing suggests that Kaprex may offer a high degree of predicted cardiovascular, gastric, renal, and liver safety.*
Provides effective joint relief that is worry-free.*
Modulates prostaglandin E2 (PGE2) production at specific target cells.*
Features selective kinase response modulators (SKRMs) in the form of tetrahydro-iso-alpha acids (THIAA) to modulate kinase activity in favor of good health.*
The ingredient synergy of Tetrase®, oleanolic acid, and rosemary provide efficacy at a low dose for a maximum cost-effectiveness.
Take one softgel two times daily with food or as directed by your healthcare practitioner.
Serving Size: 1 Softgel
A proprietary blend of:350 mgTetrase® (Tetrahydro-iso-alpha acids complex*, from hops) (Humulus lupulus L.)Rosemary (Rosmarinus officinalis) Leaf ExtractOleanolic Acid (from olive leaf extract, Olea europaea)
Other Ingredients: Olive oil, gelatin, glycerin, yellow beeswax, water, sodium copper chlorophyllin
CAUTION: Do not use if pregnant, nursing, or if taking anticoagulants. If taking other medication, consult your healthcare practitioner before use. Keep out of the reach of children.*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
This product is manufactured in a facility that produces products containing soy, dairy, egg, nuts, fish and crustacean shellfish.
†U.S. Patent Nos. 7,195,785; 7,205,151.
In order to ensure proper use of our high-quality nutritional supplements, Metagenics only sells to licensed healthcare practitioners. The products listed in this online catalog are available in the United States and may not be available in other countries. In addition, certain formulas may be slightly different outside the US.
|
|
|
 |
|
 |
|
|
|
